Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…
Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership
Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership…
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
Lucid Diligence Brief: Regeneron Otarmeni FDA approval
Lucid Diligence Brief: Regeneron Otarmeni FDA approval Professional audiences…
Lucid Diligence Brief: Avalyn Pharma IPO
Lucid Diligence Brief: Avalyn Pharma IPO Professional audiences only. Not…
Vaccines Today—April 24, 2026
This weekly update in vaccines and immunotherapy covers recent developments…
Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing
Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…